Earnings Insights · AMGN · Q3 FY2026
Amgen Q3 2026 Earnings: Growth Portfolio Offsets Biosimilar Erosion as IMDELLTRA Opportunity Expands
By AlgovestIQ ResearchPublished
Read Amgen’s results announcement (Form 8-K, filed Nov 3, 2026)
Key earnings findings
Amgen (AMGN) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Amgen reported Q3 FY2026 revenue of $10.37B against the $10.07B analyst estimate, a 3.0% beat, and EPS of $6.45 against the $5.79 analyst estimate, a 11.4% beat.
- Management expects full-year non-GAAP operating margin as a percentage of product sales to be roughly 45% to 46%.
- AMGN closed at $478.48 on Nov 4, 2026, up 3.7% from $461.26 on Nov 3, 2026, the last close before the results were released.
Sources: Amgen results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Amgen beat earnings expectations?
- EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
- Revenue surprise across the last 8 reported quarters has ranged from 0.5% to 6.7%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Amgen reported third-quarter revenue of $10.4B, up 8% year over year, while GAAP diluted EPS rose 19% to $7.08 and non-GAAP EPS increased 14% to $6.45. Growth in Repatha, EVENITY, TEZSPIRE, UPLIZNA and oncology products more than offset sharp biosimilar-driven declines in Prolia and XGEVA.
The quarter reinforced that Amgen’s near-term growth is increasingly supported by a broader group of newer medicines, rather than a handful of legacy franchises. However, the underlying margin picture was steadier than the GAAP figures suggest, free cash flow declined, and the company continues to carry $54.0B of debt while funding late-stage pipeline investments and manufacturing capacity.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Total revenue | $10.4B | +8% YoY |
| Product sales | $9.9B | +8% YoY |
| GAAP diluted EPS | $7.08 | +19% YoY |
| Non-GAAP diluted EPS | $6.45 | +14% YoY |
| GAAP operating income | $3.7B | +47% YoY |
| GAAP operating margin | 37.5% | +9.9 pts. YoY |
| Non-GAAP operating income | $4.7B | +9% YoY |
| Non-GAAP operating margin | 47.3% | +0.2 pts. YoY |
| Free cash flow | $3.7B | -14% YoY |
| Repatha sales | $1.1B | +37% YoY |
| EVENITY sales | $751M | +39% YoY |
| TEZSPIRE sales | $538M | +43% YoY |
| UPLIZNA sales | $451M | +191% YoY |
| IMDELLTRA sales | $406M | +128% YoY |
| Prolia sales | $632M | -45% YoY |
| XGEVA sales | $288M | -47% YoY |
The Bigger Story
Amgen’s investment case is becoming more dependent on execution across a diversified group of growth medicines and the conversion of a large late-stage pipeline into commercial products. The company said its six key growth drivers increased 27% year over year and represented more than 70% of third-quarter product sales, while 17 products delivered double-digit growth.
That diversification matters because biosimilar competition is now materially eroding older denosumab franchises. Prolia sales fell 45% to $632M and XGEVA declined 47% to $288M as multiple biosimilars launched globally. These declines are substantial enough that Amgen must sustain strong volume-led growth in newer products to keep total revenue advancing.
The most consequential strategic development was the Phase III DeLLphi-305 result for IMDELLTRA in first-line maintenance treatment of extensive-stage small cell lung cancer. Management said IMDELLTRA plus IMFINZI produced median overall survival of 21.1 months, compared with 12.7 months for IMFINZI alone. The company is preparing regulatory submissions, but the potential first-line opportunity remains dependent on approvals, guideline adoption and commercial execution.
Revenue and Operating Performance
Product sales rose 8% to $9.9B, driven primarily by volume growth across Amgen’s newer cardiovascular, bone-health, inflammation, rare-disease and oncology medicines.
Repatha was a major contributor, with sales increasing 37% to $1.1B. Management said U.S. weekly new-to-brand prescriptions increased more than 60% from the prior year, supported by use in secondary prevention and high-risk primary prevention. Updated cardiovascular guidelines and new outcomes data may support further adoption, although revenue growth will still depend on physician uptake and payer access.
EVENITY sales rose 39% to $751M, also driven by volume. Management cited expanding prescriber adoption in the U.S. and continued category leadership in Japan. TEZSPIRE increased 43% to $538M, reflecting demand in severe uncontrolled asthma. The company said U.S. TEZSPIRE new-to-brand prescriptions grew 15%, compared with 3% growth in the broader severe asthma market.
Rare-disease growth was led by UPLIZNA, whose sales nearly tripled to $451M. The increase was primarily volume-driven, with management pointing to demand across approved indications and growth in generalized myasthenia gravis. KRYSTEXXA sales increased 31% to $419M, largely due to higher net selling prices, while TEPEZZA declined 6% to $526M because the prior-year quarter included higher inventory levels.
In oncology, IMDELLTRA sales more than doubled to $406M, BLINCYTO rose 27% to $496M, and Vectibix grew 18% to $335M. IMDELLTRA remains relatively early in its commercial rollout, but an FDA label update reducing the initial monitoring recommendation from 22 to 24 hours to 6 to 8 hours could reduce a practical adoption barrier in community oncology settings.
Not all gains were volume-led. Established products, including Aranesp, Neulasta and Parsabiv, grew 14% to $606M, driven by 19% higher net selling prices despite a 3% volume decline. Enbrel sales rose 5% to $611M, but that increase reflected favorable changes in estimated sales deductions and higher inventory levels. Its underlying pricing remained under pressure, including from Medicare Part D price setting under the Inflation Reduction Act.
Profitability and Margins
GAAP operating income rose 47% to $3.7B, and GAAP operating margin expanded 9.9 percentage points to 37.5%. Much of that improvement reflected lower acquisition-related amortization expense and lower manufacturing costs, as well as a sharp reduction in other operating expenses.
The non-GAAP results present a more muted view of underlying margin expansion. Non-GAAP operating income increased 9% to $4.7B, while non-GAAP operating margin increased only 0.2 percentage points to 47.3%.
Non-GAAP cost of sales rose 15%, with cost of sales as a percentage of product sales increasing 1.1 percentage points to 19.3%. Amgen attributed this to higher profit-sharing expense and sales mix, partly offset by lower manufacturing costs. That pressure was largely offset by lower SG&A spending, which declined 1% on a non-GAAP basis.
R&D expense increased 11% to $2.1B on both GAAP and non-GAAP measures. The spending increase reflects investment in research, early pipeline programs and business development, including development of MariTide, dazodalibep, xaluritamig and expanded programs for marketed medicines.
GAAP EPS growth also benefited from a lower tax rate and operating-margin expansion. However, GAAP other income included $1.5B of net gains from equity investments, compared with $2.0B in the prior-year quarter. These gains are excluded from non-GAAP earnings and should not be treated as operating performance.
Demand, Customers and Pricing
The quarter showed strong demand across several products with sizable remaining treatment populations, according to management. Repatha, EVENITY and TEZSPIRE all posted volume-led growth, while UPLIZNA continued to expand across approved indications and markets.
Pricing was mixed. KRYSTEXXA and established products benefited from higher net selling prices, while Prolia, XGEVA, Enbrel, Otezla, TAVNEOS and PAVBLU faced varying degrees of price pressure, unfavorable sales deductions or both. PAVBLU sales rose 41% to $300M on 71% volume growth, but its net selling price declined 18%.
This split is important: Amgen’s growth medicines are increasingly carrying the portfolio, but price and volume erosion from biosimilar competition remains a recurring headwind for mature brands.
What is Amgen’s guidance for full-year 2026?
Amgen raised its full-year revenue and non-GAAP EPS outlook. Management now expects:
- Total revenue of $38.9B to $39.7B
- GAAP EPS of $18.34 to $19.28
- Non-GAAP EPS of $22.90 to $23.70
- GAAP tax rate of 14.5% to 16.0%
- Non-GAAP tax rate of 15.0% to 16.5%
- Capital expenditures of approximately $2.6B
- Share repurchases not to exceed $3.0B
Management expects full-year non-GAAP operating margin as a percentage of product sales to be roughly 45% to 46%. It also expects a meaningful sequential increase in fourth-quarter operating expenses, including higher cost of sales from product mix and profit-sharing expense, as well as higher SG&A due to the timing of investments and continued commercial spending.
Management said it does not anticipate a step-down in operating margin in 2027 compared with its 2026 guidance range. That is an outlook statement rather than a formal 2027 financial forecast.
Balance Sheet, Cash Flow and Capital
Third-quarter operating cash flow declined to $4.2B from $4.7B a year earlier, while free cash flow fell to $3.7B from $4.2B. Amgen attributed the decline primarily to working-capital timing, noting that the prior-year period benefited from the timing of rebates and collections.
Capital expenditures increased to $587M from $436M. Management said investment is being directed toward manufacturing sites in North Carolina, Ohio and Puerto Rico, as Amgen expands capacity for commercial growth and prepares for a potential MariTide launch.
Cash and cash equivalents totaled $13.2B at September 30, up from $9.1B at year-end 2025. Debt outstanding was $54.0B, down modestly from $54.6B at year-end. The company paid $1.4B in dividends during the quarter and did not repurchase stock. Its quarterly dividend was increased 6% year over year to $2.52 per share.
What Investors Should Watch
1. Durability of Growth-Medicine Momentum
Repatha, EVENITY, TEZSPIRE, UPLIZNA and IMDELLTRA are increasingly responsible for offsetting losses in mature franchises. Sustained volume growth in these products is necessary as Prolia and XGEVA continue to face biosimilar competition.
2. IMDELLTRA’s First-Line Regulatory Path
The DeLLphi-305 survival result could significantly expand IMDELLTRA’s addressable market if regulators approve first-line maintenance use. Investors should monitor filing timing, regulatory decisions, labeling and the pace of guideline incorporation.
3. MariTide’s Phase III Readouts and Manufacturing Spend
Amgen is increasing manufacturing capacity ahead of a potential MariTide launch while the obesity medicine remains in Phase III development. The key future evidence will be efficacy, tolerability, dosing convenience and the eventual ability to secure payer coverage.
4. Underlying Margin Stability
GAAP margin expanded sharply, but non-GAAP operating margin was nearly flat. Fourth-quarter cost-of-sales and SG&A increases will test whether Amgen can sustain its stated 45% to 46% full-year non-GAAP operating-margin range while continuing to fund pipeline expansion.
5. Free Cash Flow and Debt Reduction
Amgen retains substantial liquidity, but free cash flow declined year over year and debt remains elevated at $54.0B. Capital allocation between dividend growth, share repurchases, debt management, manufacturing investment and potential business development will remain important.
AlgovestIQ Takeaway
Amgen delivered a stronger quarter on the headline numbers, with 8% revenue growth, double-digit EPS growth and broad-based contributions from newer products. The commercial portfolio is becoming more balanced, with Repatha, EVENITY, TEZSPIRE, UPLIZNA, BLINCYTO and IMDELLTRA offsetting the erosion of older denosumab franchises.
The more important development is the potential expansion of IMDELLTRA into first-line small cell lung cancer. The DeLLphi-305 survival result, if translated into regulatory approval and rapid clinical adoption, could materially change the drug’s long-term revenue opportunity. Reduced monitoring requirements may also make use more feasible outside major academic treatment centers.
Still, the quarter does not eliminate the portfolio’s core risks. Prolia and XGEVA declines were severe, pricing remains uneven across mature products, and non-GAAP operating-margin expansion was limited. Amgen is also investing heavily in R&D and manufacturing ahead of several pipeline opportunities that have not yet generated revenue.
The central investment question is whether the company can maintain growth in its current commercial drivers while converting its late-stage pipeline, particularly IMDELLTRA and MariTide, into durable new revenue streams. Continued volume growth in the core portfolio, approval progress for IMDELLTRA, and eventual Phase III data from MariTide would strengthen that case. Slower uptake, deeper biosimilar erosion, pipeline setbacks or sustained pressure on underlying margins would weaken it.
How did AMGN stock react?
AMGN closed at $478.48 on Nov 4, 2026, up 3.7% from $461.26 on Nov 3, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 3, 2026 (before release) | $461.26 | — |
| Nov 4, 2026 | $478.48 | +3.7% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- PFEPfizer Q3 2026 Earnings: Core Products Offset COVID Declines as Guidance RisesNov 3, 2026
- NVONovo Q3 2026 Earnings: GLP-1 Volumes Recover as Guidance Rises AgainNov 4, 2026
- ABBVAbbVie Q3 2026 Earnings: Skyrizi and Rinvoq Drive Another Guidance IncreaseOct 30, 2026
- LLYEli Lilly Q3 2026 Earnings: Guidance Rises as Mounjaro and Zepbound Drive $24.4B QuarterOct 29, 2026
- MRKMerck Q3 2026 Earnings: Sales Growth Holds, but Purchase Timing and Higher Investment Pressure EPSOct 29, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Amgen Q3 FY2026 earnings call transcript, as of Nov 3, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Amgen Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 3, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 3, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.